3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neuroblastoma
2
Lymphoma
2
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metabolic Diseases
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunologic Deficiency Syndromes
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Anemia, Aplastic
1
Interventions
Carboplatin
5
Nivolumab
4
pembrolizumab
3
Pemetrexed
3
Ipilimumab
3
fludarabine
2
atezolizumab
2
Cyclophosphamide
2
Cisplatin
2
tremelimumab
1
sotorasib
1
osimertinib
1
olaparib
1
durvalumab
1
Tumor Burden
1
Thoracoscopy
1
Tablets
1
Saline Solution
1
Quality of Life
1
Observation
1
Magnesium Sulfate
1
Injections
1
Influenza Vaccines
1
Histocompatibility Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Exercise Therapy
1
Combined Modality Therapy
1
Cell- and Tissue-Based Therapy
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Mesothelioma
×
Influenza Vaccines
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled